2.96
0.24 (8.82%)
| Penutupan Terdahulu | 2.72 |
| Buka | 2.68 |
| Jumlah Dagangan | 961,200 |
| Purata Dagangan (3B) | 304,011 |
| Modal Pasaran | 1,827,802,368 |
| Harga / Buku (P/B) | 20.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 31 Mar 2025 |
| EPS Cair (TTM) | -0.390 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 522.50% |
| Nisbah Semasa (MRQ) | 0.200 |
| Aliran Tunai Operasi (OCF TTM) | -125.74 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -134.61 M |
| Pulangan Atas Aset (ROA TTM) | -17.81% |
| Pulangan Atas Ekuiti (ROE TTM) | -242.61% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | IMMUNOTECH-B | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.63 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| IMMUNOTECH-B | 2 B | - | - | 20.15 |
| CSTONE PHARMA-B | 14 B | - | - | 27.87 |
| CKLIFE SCIENCES | 7 B | - | - | 1.88 |
| VIVA BIOTECH | 4 B | - | 28.57 | 0.940 |
| ANTENGENE-B | 3 B | - | - | 2.84 |
| SINOMAB BIO-B | 2 B | - | - | 4.23 |
|
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 72.90% |
| % Dimiliki oleh Institusi | 6.41% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |